陳肇始:豁免科興醫學期刊數據絕非降低標準
食物及衛生局局長陳肇始表示,科興已向政府提交部分曾交國家藥監局審批的第三期臨床試驗數據,爭取在農曆新年前交由疫苗顧問專家委員會審議,並盡快批核作緊急使用,強調政府豁免科興在醫學期刊刊登研究數據絕非降低標準,指出顧問專家委員會將小心審視每隻疫苗的所有數據,希望公眾對專家小組予以信心。
陳肇始在電台節目中表示,正與復星醫藥(02196.HK)及德國藥廠BioNTech緊密聯繫,希望疫苗能在本月底送貨,爭取在農曆新年過後安排市民接種。
她又提到,18區疫苗接種中心的籌備工作如火如荼,創科局將推出預約接種疫苗的網上平台,讓市民預約及提醒他們接種第二劑疫苗,並會邀請私家醫生參與疫苗接種計劃,並安排使用不需冷藏在攝氏負70度的科興疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.